Filana Therapeutics (FLNA) Common Equity (2010 - 2026)
Filana Therapeutics (FLNA) posted quarterly Common Equity of $63.6 million for Q2 2026, down 27.69% year-over-year from $88.0 million in Q2 2025, and down 6.65% quarter-over-quarter from $68.1 million in Q1 2026.
Filana Therapeutics (FLNA) Common Equity (2010 - 2026) Analysis & Trends
Filana Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $63.6 million for Q2 2026.
- In Q2 2026, Common Equity fell 27.69% year-over-year to $63.6 million; the TTM figure through Jun 2026 stood at $63.6 million (down 27.69% YoY), while the FY2025 annual figure was $74.4 million, down 48.94% from the prior year.
- Common Equity for Q2 2026 stood at $63.6 million, down from $68.1 million in the prior quarter.
- The five-year high for Common Equity was $237.1 million in Q1 2022, with the low at $63.6 million in Q2 2026.
- The 5-year median for Common Equity is $150.4 million (2023), against an average of $146.7 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity sank 61.47% in 2024, then jumped 62.37% in 2025.
- Filana Therapeutics' Common Equity stood at $227.5 million in 2022, then tumbled by 39.58% to $137.5 million in 2023, then rose by 5.99% to $145.7 million in 2024, then sank by 48.94% to $74.4 million in 2025, then retreated by 14.51% to $63.6 million in 2026.
- Business Quant data shows FLNA's Common Equity at $63.6 million in Q2 2026, $68.1 million in Q1 2026, and $74.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Filana Therapeutics | 46.00 Mn | 46.00 Mn | - | 63.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 63.61 Mn |
| Mar 31, 2026 | 68.14 Mn |
| Dec 31, 2025 | 74.40 Mn |
| Sep 30, 2025 | 81.57 Mn |
| Jun 30, 2025 | 87.97 Mn |
| Mar 31, 2025 | 127.62 Mn |
| Dec 31, 2024 | 145.70 Mn |
| Sep 30, 2024 | 166.64 Mn |
| Jun 30, 2024 | 188.97 Mn |
| Mar 31, 2024 | 78.60 Mn |
| Dec 31, 2023 | 137.47 Mn |
| Sep 30, 2023 | 155.12 Mn |
| Jun 30, 2023 | 179.35 Mn |
| Mar 31, 2023 | 204.01 Mn |
| Dec 31, 2022 | 227.54 Mn |
| Sep 30, 2022 | 198.72 Mn |
| Jun 30, 2022 | 218.37 Mn |
| Mar 31, 2022 | 237.09 Mn |
| Dec 31, 2021 | 253.92 Mn |
| Sep 30, 2021 | 267.57 Mn |